Objective
The human pathogen Acinetobacter baumannii represents a deadly threat to human health. Despite its established clinical relevance, the pathogenicity of this nosocomial superbug is poorly understood. The biphasic amoeba Acanthamoeba castellanii is a cellular infection model broadly used to decipher the virulence mechanisms of human pathogens, as bacterial resistance upon amoebal predation (grazing) are often correlated with their pathogenicity potential in human. However, high-throughput screening approaches to investigate the virulence mechanisms of A. baumannii using this amoeba in an infection context are still lacking.
This project aims at applying original large-scale screening approaches to identify A. baumannii virulence factors using the amoeba A. castellanii as host-pathogen system. The proposed experimental set up allows monitoring the outcome of the bacteria-amoebae interactions in qualitative and quantitative manners, at both population and single cell levels. Virulence induction of A. baumannii, as well as the use of successful clinical isolates will be tested using several complementary grazing assays. Precise localization of A. baumannii reporter strains will be done on both trophozoite and cyst stages of A. castellanii, complemented with (i) real-time and live-cell fluorescence imaging as well as (ii) electron microscopy techniques. Viability assays for both bacteria and amoebae will be done to understand the symbiotic outcome of this interaction. The global resistance potential of A. baumannii will be assessed by (i) Tn-seq analysis and (ii) high-throughput screen of individual mutant strains, followed by in depth mechanistic studies on validated attenuated strains.
This project will shed light on the yet unknown global virulence mechanisms of A. baumannii by generating original screening methods using A. castellanii as an infection cellular model.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences medical biotechnology genetic engineering gene therapy
- medical and health sciences basic medicine immunology
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance multidrug resistance
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2016
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
5000 Namur
Belgium
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.